Accelerating Progress in Pharma and Biotech: A Closer Look at Surrogate Endpoints and Promising Therapies - Pharma and BioTech Daily

Summary4 min read

Pharma and BioTech Daily Summary: Accelerating Progress in Pharma and Biotech

Podcast Information

Title: Pharma and BioTech Daily
Host/Author: Pharma and BioTech News
Description: This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: Pharma and BioTech Daily
Episode: Accelerating Progress in Pharma and Biotech: A Closer Look at Surrogate Endpoints and Promising Therapies
Release Date: December 10, 2024

Overview of the FDA's Accelerated Approval Pathway

The podcast episode delves into the FDA's Accelerated Approval Pathway, a regulatory mechanism established in 1992 to expedite the availability of drugs for serious conditions. This pathway has been instrumental in bringing over 200 new drugs to the market based on surrogate endpoints—biomarkers intended to predict clinical benefits. “The FDA's Accelerated Approval Pathway has allowed over 200 new drugs to come to market based on surrogate endpoints” ([00:00]).

Recent Successes and Concerns

While the pathway has facilitated the approval of numerous therapies, recent developments have sparked concerns about its reliability. Notable withdrawals, such as Pfizer's Oxpreda and Takeda's Excavatee, have highlighted potential risks associated with relying on surrogate endpoints. Despite these setbacks, the program boasts a robust track record, with "over half of accelerated approvals converting to full approval" ([00:00]).

Expansion into New Therapeutic Areas

Originally predominantly used for cancer treatments, the Accelerated Approval Pathway is now extending its reach into other critical areas, including neurological and rare diseases. This expansion signifies the pathway's growing importance in addressing unmet medical needs beyond oncology.

Recent Failures and Calls for Improvement

The episode discusses the recent failure of confirmatory trials for drugs like sareptaselovidis, which has intensified calls from experts for the pathway's refinement. Experts advocate for "tighter timelines and better biomarkers for surrogate endpoints to improve the program" ([00:00]). These improvements aim to enhance the predictiveness of surrogate markers and ensure that accelerated approvals translate into genuine clinical benefits.

Future of the Accelerated Approval Pathway

As the pathway undergoes scrutiny, questions emerge regarding its optimal usage frequency and the specific disease areas it should prioritize next. The future of the Accelerated Approval Pathway hinges on balancing rapid access to potentially life-saving drugs with the necessity of ensuring their long-term efficacy and safety.

Notable Drug Developments

Abyvi’s Tavopodon: Demonstrated improvements in motor functions and daily living complications in a phase three trial.
Relmoda Therapeutics: Following the failure of a key Cerevil acid, the company is exploring strategic alternatives, including a potential sale, after halting two phase three trials for a major depressive disorder drug.
Bioage: Discontinued a phase 2 obesity study, signaling a strategic pivot or reevaluation of its therapeutic approaches.
Merckx: Released promising anti-ROR1 ADC data for lymphoma treatment, indicating potential advancements in targeted cancer therapies.
Novo and Catalint: Their $16.5 billion deal received EU approval, marking a significant consolidation in the biotech sector.
Vertex and Beam: Reported progress in Sickle Cell Disease (SCD) cell and gene therapies, offering hope for more effective treatments.

Advancements in GLP1s and Amylin Analogs for Alzheimer's and Weight Loss

The podcast highlights growing evidence supporting the potential of GLP1 receptor agonists in treating Alzheimer's disease. These agents, traditionally used for weight loss and diabetes management, may offer neurological benefits. “Evidence grows for the potential of GLP1s in Alzheimer's disease” ([00:00]).

Additionally, amylin analogs are emerging as promising alternatives or complements to GLP1 receptor agonists for weight loss, boasting a cleaner tolerability profile. This development is significant as it provides more options for patients seeking effective weight management solutions with fewer side effects. “Amylin analogs are emerging as a potential alternative or complement to GLP1 receptor agonists for weight loss with a cleaner tolerability profile” ([00:00]).

Upcoming Milestones

Novo Nordisk: Phase three results are anticipated next year, which could further validate the role of GLP1s in Alzheimer's treatment.
Lily Overnovo: Achieved a weight loss victory in a head-to-head study, showcasing the efficacy of her approach in comparative trials.

Regulatory and Safety Updates

FDA Action Alerts: The FDA continues to monitor and issue alerts concerning drug safety, emphasizing the importance of vigilance in post-approval phases.
Bluebird’s Gene Therapy Skisana: The FDA is investigating the safety of Skisana, a gene therapy for hematologic malignancies, highlighting ongoing concerns about the safety profiles of advanced therapies.
Applied Therapeutics: Recently experienced a setback after the FDA rejected a rare disease drug, underscoring the high stakes and stringent standards in drug approval processes.

Promising Cancer Therapies

Companies such as AstraZeneca and Maris are developing promising cancer therapies, reflecting the continuous innovation and investment in oncology by major pharmaceutical players.

Conclusion

The episode underscores significant advancements and ongoing challenges within the biopharma industry. The potential of GLP1s in Alzheimer's disease and the emergence of amylin analogs for weight loss represent notable strides in therapeutic development. Simultaneously, the FDA’s Accelerated Approval Pathway remains a critical yet scrutinized avenue for bringing new therapies to market swiftly. Balancing rapid drug approvals with the assurance of long-term safety and efficacy remains a pivotal focus for the future of pharma and biotech.

Notable Quotes:

“The FDA's Accelerated Approval Pathway has allowed over 200 new drugs to come to market based on surrogate endpoints” ([00:00]).
“Over half of accelerated approvals converting to full approval” ([00:00]).
“Tighter timelines and better biomarkers for surrogate endpoints to improve the program” ([00:00]).
“Evidence grows for the potential of GLP1s in Alzheimer's disease” ([00:00]).
“Amylin analogs are emerging as a potential alternative or complement to GLP1 receptor agonists for weight loss with a cleaner tolerability profile” ([00:00]).

This comprehensive summary captures the key discussions, insights, and developments presented in the podcast episode, providing a clear and detailed overview for listeners and non-listeners alike.

Loading summary

Transcript1 lines

[00:00]
A
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in pharma and biotech world. The FDA's Accelerated Approval Pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxpreda and Takeda's Excavatee have raised concerns about the risks of this pathway. Despite some high profile failures, the program has a strong track record with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments, but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like sareptaselovidis have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next. Abyvi's Tavopodon showed improvement in motor and daily living complications in a phase three trial. Following the failure of another key Cerevil acid, Relmoda Therapeutics is considering strategic alternatives, including a potential sale after halting two phase three trials for a major depressive disorder drug. Other news includes Bioage discontinuing a phase 2 obesity study, Merckx promising anti ROR1 ADC data for lymphoma treatment and Novo and Catalint's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies. While evidence grows for the potential of GLP1s in Alzheimer's disease, recent studies have shown that GLP1 receptor agonists commonly used for weight loss and diabetes may have potential in treating Alzheimer's disease. Phase three results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lily Overnovo in a head to head study, FDA action alerts and promising cancer therapies from companies like AstraZeneca and Maris. The FDA is also investigating the safety of Bluebird's gene therapy Skisana for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.